EMA/HMA Task Force on Availability of Authorised Medicines for Human and Veterinary Use (TF-AAM)
Source: EMA "HMA / EMA Task Force on the Availability of Authorised Medicines for Human and Veterinary Use (2016-2024)" page, retrieved 2026-07-29 via the Tokyo relay. This P2 topic records EMA's structural role in veterinary-medicine supply availability: the HMA/EMA joint task force explicitly covered authorised veterinary medicines alongside human medicines from 2016 to end of 2024.
TF-AAM claims (verified C1 substrings of source_file)
The Heads of Medicines Agencies (HMA) / European Medicines Agency (EMA) Task Force on the Availability of Authorised Medicines for Human and Veterinary Use (TF-AAM) provided strategic and structural solutions to tackle disruptions in the supply of medicines and ensure their continued availability in the European Union (EU).(EMA's joint task-force role on medicine-supply disruptions.)It focused on the availability of authorised human and veterinary medicines, irrespective of the authorisation route.(Veterinary medicines were explicitly in scope, all authorisation routes.)It functioned between 2016 and end of 2024.(Operational period of the task force.)
Scope note
For the live EU-level shortage-notification system (post-2024) see EMA_VET_MEDICINE_SHORTAGE_ESMP. EMA's veterinary committee is the Committee for Medicinal Products for Veterinary Use (CVMP); the shortage-monitoring mechanism itself runs through ESMP.